227
Participants
Start Date
November 19, 2012
Primary Completion Date
June 22, 2016
Study Completion Date
May 18, 2023
Copanlisib (Aliqopa, BAY80-6946)
"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
Brussels
Budapest
Budapest
Bruxelles - Brussel
Sofia
Turnhout
Garran
Wilrijk
Clinton
Leuven
Seoul
Linz
Seoul
Kaposvár
Ghent
Turin
Berlin
Athens
Westbury
Berlin
Potsdam
Milan
Brescia
Madrid
Majadahonda
Brest
Marbella
Tampere
Pessac
Istanbul
Izmir
Birmingham
Izmir
Bologna
Louisville
Seville
Canton
Recklinghausen
Valencia
Münster
Detroit
Busan
Vandœuvre-lès-Nancy
Mainz
Saint Louis Park
Lille
Pierre-Bénite
Paris
Rouen
San Antonio
Aurora
Englewood
Napoli
Fort Collins
München
Gilbert
La Roche-sur-Yon
Poitiers
Oulu
Anaheim
Créteil
Seattle
Moscow
Singapore
Singapore
Saint Petersburg
Saratov
Nizhny Novgorod
Omsk
Kemerovo
Petah Tikva
Ramat Gan
Ẕerifin
Spokane
Saint John
Montreal
Montreal
Helsinki
Turku
Dresden
Hong Kong
Christchurch
Shatin
Galway
Rome
Gdynia
Krakow
Lisbon
Lisbon
Barcelona
Uddevalla
Ankara
Cambridge
Plymouth
Southampton
Harrow
Liverpool
Sutton
Birmingham
Leeds
Manchester
Romford
Lead Sponsor
Bayer
INDUSTRY